Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.58 |
| ▸ | SCN1A | P35498 | 1/20 | 0.58 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.58 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044732 | 1.00 | DRD2 (0.64) | DRD2ADRA2AADRA2BADRA2CADRA1D | |
| Lithium SCHEMBL31137836 | 0.99 | DRD2 (0.62) | DRD2ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL15988433 | 0.93 | DRD2 (0.71) | DRD2ADRA2AADRA2BADRA2CADRA1D | |
| Lithium Ion SCHEMBL30495459 | 0.89 | DRD2 (0.62) | DRD2ADRA2AADRA2BADRA2CADRA1D | |
| Lithium Ion SCHEMBL568096 | 0.89 | DRD2 (0.62) | DRD2ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL566423 | 0.86 | DRD2 (0.58) | DRD2ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL566668 | 0.86 | DRD2 (0.58) | DRD2ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL3140217 | 0.86 | DRD2 (0.55) | DRD2ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL15988329 | 0.85 | ADRA2A (0.56) | DRD2ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL15988377 | 0.84 | ADRA2A (0.58) | DRD2ADRA2AADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131640-A1 | α2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-13 | — | — | WO | claimed |
| EP-2176252-B1 | 2, 3-DIHYDROBENZO[1, 4]DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORP (FI) | 2014-09-03 | — | — | EP | claimed |
| US-8492549-B2 | 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous systeme diseases | ORION CORPORATION (FI) | 2013-07-23 | — | — | US | claimed |
| US-20100216836-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2010-08-26 | — | — | US | claimed |
| WO-2023131640-A1 | α2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-13 | — | — | WO | disclosed |
| EP-2176252-B1 | 2, 3-DIHYDROBENZO[1, 4]DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORP (FI) | 2014-09-03 | — | — | EP | disclosed |
| US-8809536-B2 | 2,3-dihydrobenzo[1,4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases | ORION CORPORATION (FI) | 2014-08-19 | — | — | US | disclosed |
| US-20140179926-A1 | 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES | ORION CORPORATION (FI) | 2014-06-26 | — | — | US | disclosed |
| US-8697723-B2 | 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases | ORION CORPORATION (FI) | 2014-04-15 | — | — | US | disclosed |
| US-20130281486-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES | ORION CORP (FI) | 2013-10-24 | — | — | US | disclosed |
| US-8492549-B2 | 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous systeme diseases | ORION CORPORATION (FI) | 2013-07-23 | — | — | US | disclosed |
| US-20100216836-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281486-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES | PMP22, NPY2R, ADRA2C | DRD2 230/4885ADRA2A 16/4885ADRA2B 42/4885 |
| US-20140179926-A1 | 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES | PMP22, NPY2R, ADRA2C | DRD2 204/4885ADRA2A 15/4885ADRA2B 42/4885 |
| US-20100216836-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | PMP22, NPY2R, ADRA2C | DRD2 277/4885ADRA2A 30/4885ADRA2B 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.